文献速递肝病

严重酒精相关性肝炎激素治疗最佳窗口:全球研究

Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.
PubMed 文献 · J Hepatol · 2021-06-21

这项全球多中心回顾性队列研究纳入3380例酒精相关性肝炎成人患者,评估糖皮质激素对不同MELD评分患者30天死亡率的影响。结果显示激素仅改善MELD 21至51患者的30天生存,最大获益见于MELD 25至39,MELD>51者无获益。

要点

  • 激素改善严重酒精相关性肝炎30天生存,最大获益见于MELD 25–39。
  • MELD 21–51范围内激素有生存获益,MELD>51者无获益。
  • 激素类型(泼尼松、泼尼松龙或甲泼尼龙)与生存获益无关。

核心结论

  • 糖皮质激素仅改善严重酒精相关性肝炎患者的30天生存,最大获益见于MELD 25至39,MELD>51者无获益。

研究设计与样本

  • 回顾性国际多中心队列研究,覆盖4大洲,纳入3380例临床和/或组织学诊断的酒精相关性肝炎成人患者。

主要发现

  • 中位年龄49(40–56)岁,76.5%为男性,79%有 underlying cirrhosis,入院中位MELD 24(19–29)。
  • 30天生存率88%(87–89),90天77%(76–78),180天72%(72–74)。
  • 1225例患者接受糖皮质激素;校正生存模型显示激素使用使30天死亡率降低41%(HR 0.59;0.47–0.74;p<0.001)。
  • 激素仅在MELD 21(HR 0.61;0.39–0.95;p=0.027)至51(HR 0.72;0.52–0.99;p=0.041)患者中改善生存。
  • 最大效应(21–30%生存获益)见于MELD 25(HR 0.58;0.42–0.77;p<0.001)至39(HR 0.57;0.41–0.79;p<0.001);MELD>51无激素获益;激素类型与生存获益无关(p=0.247)。

临床怎么用

  • 对严重酒精相关性肝炎(MELD>20)患者,激素治疗应聚焦MELD 25–39以获得最大30天生存获益。
  • MELD 21–51范围内可考虑激素,但MELD>51者不应期待激素带来生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too sick to benefit from therapy. Herein, we aimed to identify the range of MELD scores within which steroids are effective for AH. METHODS: We performed a retrospective, international multicenter cohort study across 4 continents, including 3,380 adults with a clinical and/or histological diagnosis of AH. The main outcome was mortality at 30 days. We used a discrete-time survival analysis model, and MELD cut-offs were established using the transform-the-endpoints method. RESULTS: In our cohort, median age was 49 (40-56) years, 76.5% were male, and 79% had underlying cirrhosis. Median MELD at admission was 24 (19-29). Survival was 88% (87-89) at 30 days, 77% (76-78) at 90 days, and 72% (72-74) at 180 days. A total of 1,225 patients received corticosteroids. In an adjusted-survival-model, corticosteroid use decreased 30-day mortality by 41% (hazard ratio [HR] 0.59; 0.47-0.74; p <0.001). Steroids only improved survival in patients with MELD scores between 21 (HR 0.61; 0.39-0.95; p = 0.027) and 51 (HR 0.72; 0.52-0.99; p = 0.041). The maximum effect of corticosteroid treatment (21-30% survival benefit) was observed with MELD scores between 25 (HR 0.58; 0.42-0.77; p <0.001) and 39 (HR 0.57; 0.41-0.79; p <0.001). No corticosteroid benefit was seen in patients with MELD >51. The type of corticosteroids used (prednisone, prednisolone, or methylprednisolone) was not associated with survival benefit (p = 0.247). CONCLUSION: Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39. LAY SUMMARY: Alcohol-associated hepatitis is a condition where the liver is severely inflamed as a result of excess alcohol use. It is associated with high mortality and it is not clear whether the most commonly used treatments (corticosteroids) are effective, particularly in patients with very severe liver disease. In this worldwide study, the use of corticosteroids was associated with increased 30-day, but not 90- or 180-day, survival. The maximal benefit was observed in patients with an MELD score (a marker of severity of liver disease; higher scores signify worse disease) between 25-39. However, this benefit was lost in patients with the most severe liver disease (MELD score higher than 51).

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Arab JP, Díaz LA, Baeza N, et al. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. J Hepatol. 2021. PMID: 34166722. doi:10.1016/j.jhep.2021.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。